Piper Sandler: 'Own Karyopharm Therapeutics (KPTI) for Myelofibrosis Data in 2H:25'; PT Split-Adjusted
Tweet Send to a Friend
Piper Sandler analyst Edward A. Tenthoff lowered the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $15.00 (from $75.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
